THERAVECTYS is a vaccine biotech company that designs and validates safe and efficient T-cell vaccines based on its proprietary lentiviral vector platform. Translating 20+ years of research on lentiviral vectors into actionable innovation, we bring a spectacular paradigm shift in vaccinology and commit to preventing and curing major chronic infections and cancers with high-impact on global health.

Vision

Curing major chronic infections and cancers at an affordable cost, and finally tackling the global HIV epidemic

Science

Lentiviral proprietary platform to design safe and efficient T-cell vaccines

Development

On-going Preclinical Proof-of-Concepts in Infectious Diseases, Virus-Induced Cancers and Solid Tumors